RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells

Epigenetics

Volumn 9, Issue 11, 2014, Pages 1496-1503

  Mezzanotte, Jessica J ^a   Hill, Victoria ^b   Lee Schmidt, M ^a   Shinawi, Thoraia ^b   Tommasi, Stella ^d   Krex, Dietmar ^c   Schackert, Gabriele ^c   Pfeifer, Gerd P ^d   Latif, Farida ^b   Clark, Geoffrey J ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Brain metastases; Invasion; MAPK; Melanoma; Ras; RASSF

Indexed keywords

B RAF KINASE; MACROPHAGE ACTIVATING FACTOR; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 6; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; MACROPHAGE STIMULATING PROTEIN; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; ONCOPROTEIN; RASSF1 PROTEIN, HUMAN; RASSF2 PROTEIN, HUMAN; RASSF6 PROTEIN, HUMAN; SCATTER FACTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BRAIN METASTASIS; BREAST TUMOR; CARCINOGENESIS; CELL INVASION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; LUNG TUMOR; METASTATIC MELANOMA; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BRAIN TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROMOTER REGION; SECONDARY; TUMOR CELL LINE;

BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MONOMERIC GTP-BINDING PROTEINS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEINS;

EID: 84922023829     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/15592294.2014.983361     Document Type: Article

References (33)

1. Regad T. Molecular and cellular pathogenesis of melanoma initiation and progression. Cell Mol Life Sci 2013; 70:4055-65; PMID:23532409; http://dx.doi. org/10.1007/s00018-013-1324-2
2. Finn L, Markovic SN, Joseph RW. Therapy for metastatic melanoma: the past, present, and future. BMC Med 2012; 10:23; PMID:22385436; http://dx.doi.org/ 10.1186/1741-7015-10-23
3. Goulart CR, Mattei TA, Ramina R. Cerebral melanoma metastases: a critical review on diagnostic methods and therapeutic options. ISRN Surg 2011; 2011:276908; PMID:22084751; http://dx.doi.org/ 10.5402/2011/276908
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54; PMID:12068308; http://dx.doi.org/10.1038/nature00766
5. Osborne JK, Zaganjor E, Cobb MH. Signal control through Raf: in sickness and in health. Cell Res 2012; 22:14-22; PMID:22143568; http://dx.doi.org/ 10.1038/cr.2011.193
6. Liang S, Sharma A, Peng HH, Robertson G, Dong C. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res 2007; 67:5814-20; PMID:17575149; http://dx.doi.org/10.1158/0008- 5472.CAN-06-4233
7. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013; 49:1297- 304; PMID:23290787; http://dx.doi.org/10.1016/j. ejca.2012.11.019
8. van der Weyden L., Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007; 1776:58-85; PMID:17692468
9. Avruch J, Praskova M, Ortiz-Vega S, Liu M, Zhang XF. Nore1 and RASSF1 regulation of cell proliferation and of the MST12 kinases. Methods Enzymol 2005; 407:290-310; PMID:16757333; http://dx.doi.org/ 10.1016/S0076-6879(05)07025-4
10. Ikeda M, Kawata A, Nishikawa M, Tateishi Y, Yamaguchi M, Nakagawa K, Hirabayashi S, Bao Y, Hidaka S, Hirata Y, et al. Hippo pathway-dependent and -independent roles of RASSF6. Sci Signal 2009; 2: ra59; PMID:19797269; http://dx.doi.org/10.1126/ scisignal.2000300
11. Yu FX,Guan KL.The Hippo pathway: regulators and regulations. Genes Dev 2013; 27:355-71; PMID:23431053; http://dx.doi.org/10.1101/gad.210773.112
12. Helmbold P, Richter AM, Walesch S, Skorokhod A, Marsch WC, Enk A, Dammann RH. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi. J Invest Dermatol 2012; 132:687-94; PMID:22113481; http://dx.doi.org/10.1038/jid.2011.380
13. Donninger H, VosMD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007; 120:3163-72; PMID:17878233; http://dx.doi.org/10.1242/jcs.010389
14. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, Ushijima T. Promoter methylation profiling of 30 genes in human malignantmelanoma. Cancer Sci 2004; 95:962-8; PMID:15596045; http://dx. doi.org/10.1111/j.1349-7006.2004.tb03184.x
15. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64:1975-86; PMID:15026333; http://dx.doi.org/10.1158/0008- 5472.CAN-03-3972
16. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, Van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003; 100:15901-5; PMID:14665696; http://dx.doi.org/10.1073/ pnas.2634067100
17. Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, Kim JL, Smith AL, Nagapudi K, Broome MA, et al. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther 2010; 9:2399-410; PMID:20663930; http://dx.doi.org/10.1158/1535- 7163.MCT-10-0181
18. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011; 10:385-94; PMID:21388974; http://dx.doi.org/10.1158/1535- 7163.MCT-10-0799
19. Iwasa H, Kudo T, Maimaiti S, Ikeda M, Maruyama J, Nakagawa K, Hata Y. The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein. J Biol Chem 2013; 288:30320-9; PMID:24003224; http://dx.doi.org/ 10.1074/jbc.M113.507384
20. Romano D, Nguyen LK, Matallanas D, Halasz M, Doherty C, Kholodenko BN, Kolch W. Protein interaction switches coordinate Raf-1 and MST2Hippo signalling. Nat Cell Biol 2014; 16:673-84; PMID:24929361; http://dx.doi.org/10.1038/ncb2986
21. Lee SJ, Lee MH, Kim DW, Lee S, Huang S, Ryu MJ, Kim YK, Kim SJ, Kim SJ, Hwang JH, et al. Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma. PLoS One 2011; 6:e16180; PMID:21249150; http:// dx.doi.org/10.1371/journal.pone.0016180
22. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796:114-28; PMID:19344752
23. Djos A, Martinsson T, Kogner P, Caren H. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. Mol Cancer 2012; 11:40; PMID:22695170; http://dx.doi.org/10.1186/1476-4598-11-40
24. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009; 8:42; PMID:19570220; http://dx.doi. org/10.1186/1476-4598-8-42
25. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003; 22:395-403; PMID:12884914; http://dx.doi.org/10.1023/A:1023781114568
26. Li C, Li F, Zhao K, Yao J, Cheng Y, Zhao L, Li Z, Lu N, Guo Q. LFG-500 inhibits the invasion of cancer cells via down-regulation of PI3KAKTNF-kappaB signaling pathway. PLoS One 2014; 9:e91332; PMID:24618693; http://dx.doi.org/10.1371/journal. pone.0091332
27. Romano D, Matallanas D, Weitsman G, Preisinger C, Ng T, Kolch W. Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res 2010; 70:1195-203; PMID:20086174; http://dx.doi.org/10.1158/0008-5472.CAN-09-3147
28. Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, Latif F. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 2005; 24:3987-94; PMID:15806169; http://dx.doi.org/ 10.1038/sj.onc.1208566
29. Hesson L, Dallol A, Minna JD, Maher ER, Latif F. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 2003; 22:947-54; PMID:12584574; http://dx.doi.org/ 10.1038/sj.onc.1206191
30. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001; 20:1509-18; PMID:11313894; http://dx.doi.org/10.1038/sj. onc.1204175
31. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ. RASSF4AD037 is a potential ras effectortumor suppressor of the RASSF family. Cancer Res 2004; 64:8688-93; PMID:15574778; http://dx.doi.org/ 10.1158/0008-5472.CAN-04-2065
32. Allen NP, Donninger H, Vos MD, Eckfeld K, Hesson L, Gordon L, Birrer MJ, Latif F, Clark GJ. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 2007; 26:6203-11; PMID:17404571
33. Morgenstern JP, Land H. A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res 1990; 18:1068; PMID:2156225; http://dx.doi.org/10.1093/nar/ 18.4.1068